- +1 551 333 1547
- +44 2070 979277
- live:skype_chat
Worst May be Over for Bio-pharma Market; How Industry Players Will Regain 10.1% Growth Cycle Again
Bio-pharma Market Latest Edition Published with Forecast to 2027- Feb 12, 2024
- Pharmaceuticals
AMA Research, a global market research and consulting organization, have released a new study titled "Bio-pharma market - Global outlook to 2027".
Industries constant focus on reducing the operational cost and increased attention on core business, and need to improve scalability are expected to shape the Global Bio-pharma market to grow at a CAGR of 10.1%.
The Sales Channel, such as Prescriptive, is boosting the Bio-pharma market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.
According to Analyst at AMA Research, the Global Bio-pharma market will experience significant growth during the forecast period due to potential opportunities lying in the market such as. Some of the important driving forces are “Increasing Acceptance for Bio-Pharmaceuticals and Significant Market Demand, The Surging Number of Chronic Diseases Patients and Geriatric Population and Rise of Antibiotic-Resistant Bacteria”.
Biopharmaceuticals are produced through biotechnology methods involving recombinant DNA techniques, purification processes and hybridoma techniques. Biopharmaceutical production involves the use of biological sources, either live organisms or their active components. A continuous rise in the number of patients suffering from critical diseases, especially in developed countries and developing countries as well, are getting more oriented towards treatments
The report provides an in-depth analysis and forecast about the industry covering the following key features:
o Industry outlook including current and future market trends, drivers, restraints, and emerging technologies
o Analyses the Global Bio-pharma market by Type (Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins and Others), by Application (Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases and Others) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
o Analyzes the top 10 players in terms of market reach, business strategy, and business focus
o Provides stakeholders’ insights and key trends (current and future) of the market
Industries constant focus on reducing the operational cost and increased attention on core business, and need to improve scalability are expected to shape the Global Bio-pharma market to grow at a CAGR of 10.1%.
The Sales Channel, such as Prescriptive, is boosting the Bio-pharma market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.
According to Analyst at AMA Research, the Global Bio-pharma market will experience significant growth during the forecast period due to potential opportunities lying in the market such as
Biopharmaceuticals are produced through biotechnology methods involving recombinant DNA techniques, purification processes and hybridoma techniques. Biopharmaceutical production involves the use of biological sources, either live organisms or their active components. A continuous rise in the number of patients suffering from critical diseases, especially in developed countries and developing countries as well, are getting more oriented towards treatments
The report provides an in-depth analysis and forecast about the industry covering the following key features:
o Industry outlook including current and future market trends, drivers, restraints, and emerging technologies
o Analyses the Global Bio-pharma market by Type (Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins and Others), by Application (Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases and Others) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
o Analyzes the top 10 players in terms of market reach, business strategy, and business focus
o Provides stakeholders’ insights and key trends (current and future) of the market
Praveen Kumar
Head & Director of Sales